Together. All the way.

Mini-Series: How Terra Fertility is elevating care and supporting outcomes with EmbryoScope and PGT-A Plus  

Embarking on an IVF (In Vitro Fertilization) journey can be emotionally complex and medically challenging. For patients, each decision along the way carries tremendous importance. One of the key elements that can support patients throughout this process is transparency, openness and information from clinics, clinicians, and laboratories. 

Mini-Series: How Terra Fertility is elevating care and supporting outcomes with EmbryoScope and PGT-A Plus  

Data from a recently published clinical study showed a significant increase in detection of euploid/diploid embryos in embryos with confirmed atypical PN using time-lapse technology with EmbryoScope and ploidy detection. 

A newly published study in F&S Reports explores a critical question in modern IVF: how does embryologist experience influence agreement with AI-driven embryo ranking, and what does this mean for clinical outcomes?

Mini-Series: How Terra Fertility is elevating care and supporting outcomes with EmbryoScope and PGT-A Plus  

In modern IVF practice, Time-lapse incubation with EmbryoScope+ and PGT-A Plus genetic testing offer complementary strategies to identify more usable embryos that may help improve transfer success.

Advancements improve identification of useable embryos, and transparency on the process

Co-author: Alexandra Frost and Vitrolife

In the intricate world of assisted reproductive technology (ART), every minute detail can significantly influence the outcome. One such detail that has garnered increasing attention is the choice of buffer during Intracytoplasmic Sperm Injection (ICSI) in the in vitro fertilization (IVF) laboratory. The meticulous research conducted by Dr. Robert J. Mendola, a distinguished expert in clinical IVF embryology, sheds light on the profound implications of different buffers on embryo development. Learn more about Dr.  Robert J. Medolas findings in this blog post. 

The CE marking on a medical device indicates that the product complies with European Union (EU) regulations. This certification highlights the fact that the product meets general safety and performance requirements as set out in Regulation (EU) 2017/745, AKA Medical Device Regulations (MDR). As well as being a legal requirement to have the CE marking in the European Economic Area (EEA), or equivalent in certain markets, it also provides reassurance that the medical device has undergone rigorous testing and assessment to ensure its safety and performance. This helps protect patients and users from potential risks associated with using non-compliant or unsafe devices.

Laser systems have been an integral part of routine IVF laboratory work for many years. Developed by Dr Klaus Rink and taken to first clinical application in 1994 in collaboration withDr Alfred Senn, the Octax laser systems quickly found worldwide adoption. Applications of Octaxlaser systems include assisted hatching / assisted thinning, blastocyst collapsing, trophectoderm and blastomere biopsy and last but not least sperm viability testing. In 2000 Dr Markus Montag was the firstauthor who described laser-induced immobilisation of human sperm ⁽¹⁾. In 2004 he further specified this application by describing the method of laser-assisted viability testing ⁽²⁾. 

Welcome to our blog post, where we explore the remarkable benefits of integrating time-lapse technology and specialised software in clinical settings. By combining these innovative tools, clinics worldwide are optimising workflows, gaining valuable insights, and revolutionising patient care. Carol Loscher, Laboratory Manager at Thérapie Fertility in Dublin, sharesthe valuable insight of their practice in the clinic.

EmbryoGlue is the first culture medium specifically formulated for transferring human embryos in a clinical setting, and it has been used in over 1 million fertility treatments since 2003.